Which blood pressure medication should be discontinued first: metoprolol, amlodipine, losartan, or spironolactone?

Which Blood Pressure Medication to Discontinue First

In the absence of specific clinical context (heart failure, renal dysfunction, hyperkalemia, or bradycardia), amlodipine should generally be discontinued first, as it lacks the mortality benefit and organ-protective effects demonstrated by the other three medications.

Clinical Decision Framework

The order of discontinuation depends critically on your patient's specific clinical profile. Here's how to approach this systematically:

If Patient Has Heart Failure with Reduced Ejection Fraction (HFrEF)

Never discontinue medications in this order of priority:

1. Spironolactone - Provides 30% mortality reduction (NNT=9 over 2 years) in severe HF 1
2. Losartan (or any ACE-I/ARB) - Reduces cardiovascular death and HF hospitalization by 23% 1
3. Metoprolol - Essential for mortality benefit in HFrEF 1
4. Amlodipine - Can be discontinued first; has no proven mortality benefit in HF and may worsen outcomes in HFrEF 2

The 2025 ESC consensus specifically emphasizes that MRAs (spironolactone) and SGLT2 inhibitors have the least impact on blood pressure and should be prioritized for continuation 3. Discontinuing spironolactone is associated with a 2-4 fold higher risk of subsequent adverse events 3.

If Patient Has Symptomatic Hypotension

According to the 2025 ESC HF consensus statement 3, follow this algorithm:

With specific clinical features:

• eGFR <30 ml/min: Reduce/stop losartan first, then spironolactone
• Potassium >5.0 mEq/L: Reduce/stop spironolactone first, then metoprolol
• Heart rate <60 bpm: Reduce/stop metoprolol first
• Heart rate >70 bpm: Reduce losartan first
• No specific clinical profile: Reduce losartan first

If Patient Has Hypertension Without Heart Failure

Discontinue in this order:

1. Amlodipine first - While effective for BP control, it lacks the comprehensive cardiovascular protection of the others 2, 4
2. Metoprolol - Beta-blockers are not first-line for uncomplicated hypertension unless there's coronary disease 2, 4
3. Losartan - ARBs provide renal protection and reduce cardiovascular events
4. Spironolactone last - Particularly valuable in resistant hypertension 5

If Patient Has Resistant Hypertension

Spironolactone should be the last medication discontinued 5. The 2024 ESC guidelines specifically recommend adding low-dose spironolactone for resistant hypertension, and it's considered a cornerstone therapy in this population.

Critical Safety Considerations

Metoprolol Discontinuation

• Never stop abruptly - Risk of rebound hypertension, tachycardia, and acute coronary events 2, 4
• Must be tapered over 1-2 weeks minimum

Spironolactone Monitoring

• Requires close monitoring of potassium and renal function 1
• Stop immediately if K+ >6.0 mmol/L or creatinine >310 mmol/L 1
• Discontinuation increases mortality risk in HF patients 3

Losartan Considerations

• Monitor renal function, especially in patients with renal artery stenosis 6
• Can cause hyperkalemia, particularly when combined with spironolactone 6

Amlodipine Profile

• Generally well-tolerated but causes dose-related peripheral edema (more common in women) 7
• No abrupt withdrawal syndrome
• Avoid in HFrEF 2, 4

Common Pitfalls to Avoid

1. Stopping beta-blockers abruptly - Always taper metoprolol
2. Discontinuing spironolactone in HF patients - Associated with significantly worse outcomes 3
3. Ignoring the clinical context - The "right" medication to stop varies dramatically based on comorbidities
4. Not monitoring after changes - Check BP, renal function, and potassium within 1-2 weeks of any change

Practical Algorithm

Without heart failure or specific contraindications:

• Stop amlodipine → metoprolol (tapered) → losartan → spironolactone

With HFrEF:

• Stop amlodipine → consider reducing (not stopping) others based on symptoms, never discontinue spironolactone if tolerated

With symptomatic hypotension:

• Follow the 2025 ESC algorithm based on HR, K+, and eGFR 3